HILS RSI Chart
Last 7 days
-4.8%
Last 30 days
-0.8%
Last 90 days
9.8%
Trailing 12 Months
465779.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 152.6K |
2022 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jul 14, 2022 | appajosyula sireesh | gifted | - | - | -75,757 | - |
Jul 14, 2022 | appajosyula sireesh | gifted | - | - | 7,576 | - |
Jun 17, 2022 | milby randy | bought | 389 | 0.7799 | 500 | chief executive officer |
Jun 06, 2022 | milby randy | bought | 688 | 0.688463 | 1,000 | chief executive officer |
Jun 01, 2022 | milby randy | bought | 0.94 | 0.94 | 1.00 | chief executive officer |
May 25, 2022 | milby randy | bought | 786 | 0.786 | 1,000 | chief executive officer |
May 20, 2022 | milby randy | bought | 918 | 0.91825 | 1,000 | chief executive officer |
May 19, 2022 | milby randy | bought | 907 | 0.90765 | 1,000 | chief executive officer |
Apr 18, 2022 | milby randy | acquired | 24,341 | 0.101203 | 240,526 | chief executive officer |
Jan 14, 2022 | milby randy | acquired | 884,125 | 3.2 | 276,289 | chief executive officer |
Which funds bought or sold HILS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Feb 26, 2024 | Virtu Financial LLC | new | - | 53,000 | 53,000 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -4,000 | - | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 10,041 | 10,041 | -% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -11,414 | - | -% |
Feb 14, 2024 | STATE STREET CORP | sold off | -100 | -5,154 | - | -% |
Feb 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | sold off | -100 | -7,549 | - | -% |
Feb 13, 2024 | Tower Research Capital LLC (TRC) | new | - | 688 | 688 | -% |
Feb 13, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -3,813 | - | -% |
Feb 09, 2024 | UBS Group AG | sold off | -100 | -8,766 | - | -% |
Feb 09, 2024 | WELLS FARGO & COMPANY/MN | new | - | 3.00 | 3.00 | -% |
Unveiling Hillstream BioPharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Hillstream BioPharma, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Hillstream BioPharma, Inc. News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 |
Revenue | 102.9% | 58.00 | 28.00 | 34.00 | 32.00 | - |
Operating Expenses | 37.2% | 2,531 | 1,845 | 2,365 | 2,714 | 1,766 |
S&GA Expenses | 13.4% | 1,538 | 1,357 | 1,334 | 1,667 | 1,083 |
R&D Expenses | 103.4% | 993 | 488 | 1,031 | 1,048 | 683 |
Interest Expenses | -89.9% | 354* | 3.00 | 7.00 | 6.00 | - |
Net Income | -35.9% | -2,473 | -1,820 | -2,336 | -2,688 | -1,766 |
Net Income Margin | -Infinity% | -61.06* | - | - | - | - |
Free Cashflow | -55.6% | -1,400 | -900 | -1,535 | -3,464 | -892 |
Balance Sheet | |||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 |
Assets | 245.6% | 10,946 | 3,167 | 4,599 | 4,722 | 6,689 | 8,018 | 10,248 | 12,091 | 622 | - |
Current Assets | 245.6% | 10,946 | 3,167 | 4,599 | 4,722 | 6,689 | 8,018 | 10,248 | 12,091 | 622 | 295 |
Cash Equivalents | 306.7% | 10,935 | 2,689 | 3,904 | 3,569 | 6,511 | 7,597 | 9,484 | 11,122 | 4.00 | 192 |
Liabilities | 28.7% | 1,815 | 1,410 | 1,530 | 1,521 | 1,145 | 902 | 1,208 | 1,752 | 5,307 | 4,012 |
Current Liabilities | 28.7% | 1,815 | 1,410 | 1,530 | 1,521 | 1,145 | 902 | 1,208 | 1,752 | 4,534 | 2,725 |
Shareholder's Equity | 419.7% | 9,131 | 1,757 | 3,069 | 3,201 | 5,544 | 7,116 | 9,040 | 10,339 | -4,684 | - |
Retained Earnings | -11.1% | -24,703 | -22,229 | -20,409 | -18,072 | -15,384 | -13,617 | -11,490 | -9,853 | -6,911 | -4,704 |
Additional Paid-In Capital | 40.9% | 33,904 | 24,055 | 23,547 | 21,342 | 20,998 | 20,795 | 20,554 | 20,191 | 2,226 | 986 |
Shares Outstanding | -33.0% | 11,740 | 17,512 | 16,814 | 11,514 | - | 11,532 | 11,104 | 11,364 | 6,357 | 6,357 |
Float | - | - | - | 3,900 | - | - | - | 5,600 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Cashflow From Operations | -55.6% | -1,400 | -900 | -1,500 | -3,500 | -892 | -1,548 | -1,373 | -2,742 | -7.67 | -316 | -269 | -492 | - |
Share Based Compensation | 7.9% | 170 | 158 | 158 | 345 | 202 | 241 | 339 | 19.00 | 7.00 | 4.00 | 554 | 674 | - |
Cashflow From Financing | 3257.4% | 9,662 | -306 | 1,846 | 523 | -193 | -338 | -249 | 13,846 | -33.06 | 333 | 276 | 323 | - |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses | ||
Research and development | $ 3,559,635 | $ 2,278,424 |
General and administrative | 5,895,585 | 4,603,514 |
Total operating expenses | 9,455,220 | 6,881,938 |
Loss from operations | (9,455,220) | (6,881,938) |
Other income (expense) | ||
Interest expense | (16,505) | (1,591,244) |
Interest income | 152,631 | |
Total other income (expense), net | 136,126 | (1,591,244) |
Net loss | $ (9,319,094) | $ (8,473,182) |
Net loss per share: | ||
Basic | $ (7.14) | $ (18.72) |
Diluted | $ (7.14) | $ (18.72) |
Weighted average number of common shares outstanding: | ||
Basic | 1,305,437 | 452,686 |
Diluted | 1,305,437 | 452,686 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash | $ 10,935,352 | $ 6,510,534 |
Prepaid expenses and other current assets | 11,041 | 178,094 |
Total current assets | 10,946,393 | 6,688,628 |
Total assets | 10,946,393 | 6,688,628 |
Current liabilities | ||
Accounts payable | 908,577 | 954,505 |
Accrued expenses | 906,469 | 190,468 |
Total current liabilities | 1,815,046 | 1,144,973 |
Total liabilities | 1,815,046 | 1,144,973 |
Commitments and contingencies (see Note 9) | ||
Stockholders’ equity | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022 | ||
Common stock, $0.0001 par value, 250,000,000 shares authorized,11,743,309 shares and 464,213 shares issued and 11,739,676 shares and 460,580 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | 1,175 | 46 |
Additional paid-in capital | 33,903,663 | 20,998,006 |
Accumulated deficit | (24,703,526) | (15,384,432) |
Treasury stock, at cost, 3,633 shares held in treasury as of December 31, 2023 and December 31, 2022 | (69,965) | (69,965) |
Total stockholders’ equity | 9,131,347 | 5,543,655 |
Total liabilities and stockholders’ equity | $ 10,946,393 | $ 6,688,628 |